Photo of Rachel Freedman,

Rachel Freedman

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-4587
Fax: (617) 632-1930


rafreedman@partners.org

Rachel Freedman

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Assistant Professor, Medical Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

I joined the faculty at Dana-Farber in 2009 after completing my fellowship at our program. I specialize in the treatment of breast cancer and see patients in the Susan F. Smith Center for Women's Cancers. My research focuses on improving the care of vulnerable patient populations who are often under-represented in clinical trials to date and who often have worse cancer outcomes compared with other patients with breast cancer, including older women and minority women. I am also interested in novel therapeutics and am the Principal Investigator for several trials in the adjuvant and metastatic disease setting.

Publications

Powered by Harvard Catalyst
  • Freedman RA, Viswanath K, Vaz-Luis I, Keating NL. Learning from social media: utilizing advanced data extraction techniques to understand barriers to breast cancer treatment. Breast Cancer Res Treat 2016. PubMed
  • Di Meglio A, Freedman RA, Lin NU, Barry WT, Metzger-Filho O, Keating NL, King TA, Sertoli MR, Boccardo F, Winer EP, Vaz-Luis I. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat 2016; 157:587-96. PubMed
  • Shields H, Li J, Pelletier S, Wang H, Freedman R, Mamon H, Ng A, Freedman A, Come S, Avigan D, Huberman M, Recht A. Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. 2016. PubMed
  • Freedman RA, Kouri EM, West DW, Lii J, Keating NL. Association of Breast Cancer Knowledge With Receipt of Guideline-Recommended Breast Cancer Treatment. J Oncol Pract 2016; 12:e613-25. PubMed
  • Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, DeSantis S, Barry WT, Golshan M. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. J Clin Oncol 2016; 34:1190-6. PubMed
  • Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 2016; 34:945-52. PubMed
  • Wong SM, Freedman RA, Sagara Y, Aydogan F, Barry WT, Golshan M. Growing Use of Contralateral Prophylactic Mastectomy Despite no Improvement in Long-term Survival for Invasive Breast Cancer. Ann Surg 2016. PubMed
  • Keating NL, Kouri EM, He Y, Freedman RA, Volya R, Zaslavsky AM. Location Isn't Everything: Proximity, Hospital Characteristics, Choice of Hospital, and Disparities for Breast Cancer Surgery Patients. Health Serv Res 2016. PubMed
  • Freedman RA, Fedewa SA, Punglia RS, Lin CC, Ward EM, Jemal A, Sineshaw HM. Factors associated with radiation therapy incompletion for patients with early-stage breast cancer. Breast Cancer Res Treat 2016; 155:187-99. PubMed
  • Freedman RA. Treatment of Breast Cancer in the Elderly. Curr Oncol Rep 2015; 17:51. PubMed
  • Wong SM, Freedman RA, Stamell E, Sagara Y, Brock JE, Desantis SD, Golshan M. Modern Trends in the Surgical Management of Paget's Disease. Ann Surg Oncol 2015; 22:3308-16. PubMed
  • Wong SM, Freedman RA, Sagara Y, Stamell EF, Desantis SD, Barry WT, Golshan M. The effect of Paget disease on axillary lymph node metastases and survival in invasive ductal carcinoma. Cancer 2015. PubMed
  • Jemal A, Lin CC, DeSantis C, Sineshaw H, Freedman RA. Temporal Trends in and Factors Associated With Contralateral Prophylactic Mastectomy Among US Men With Breast Cancer. JAMA Surg 2015. PubMed
  • Freedman RA, Kouri EM, West DW, Rosenberg S, Partridge AH, Lii J, Keating NL. Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey. Clin Breast Cancer 2015. PubMed
  • Sineshaw HM, Freedman RA, Ward EM, Flanders WD, Jemal A. Black/White Disparities in Receipt of Treatment and Survival Among Men With Early-Stage Breast Cancer. J Clin Oncol 2015; 33:2337-44. PubMed
  • Dusetzina SB, Ellis S, Freedman RA, Conti RM, Winn AN, Chambers JD, Alexander GC, Huskamp HA, Keating NL. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. J Oncol Pract 2015; 11:313-8. PubMed
  • Vaz-Luis I, Lin NU, Keating NL, Barry WT, Lii H, Winer EP, Freedman RA. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat 2015; 151:697-707. PubMed
  • Freedman RA, Kouri EM, West DW, Keating NL. Racial/Ethnic Differences in Patients' Selection of Surgeons and Hospitals for Breast Cancer Surgery. JAMA Oncol 2015; 1:222-30. PubMed
  • Freedman RA, Kouri EM, West DW, Keating NL. Racial/ethnic disparities in knowledge about one's breast cancer characteristics. Cancer 2015; 121:724-32. PubMed
  • Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, Keating NL. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 2014. PubMed
  • Vaz-Luis I, Keating NL, Lin NU, Lii H, Winer EP, Freedman RA. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol 2014; 32:927-34. PubMed
  • Freedman RA, Muss HB. Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient. 2014; 5:2-7. PubMed
  • Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat 2013; 142:405-14. PubMed
  • Freedman RA, He Y, Winer EP, Keating NL. Racial/Ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res 2013. PubMed
  • Freedman RA, Partridge AH. Management of breast cancer in very young women. Breast 2013; 22 Suppl 2:S176-9. PubMed
  • Freedman RA, Pitcher B, Keating NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB, . Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat 2013; 139:607-16. PubMed
  • Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, Wong YN, Theriault R, Keating NL. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 2013. PubMed
  • Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat 2012. PubMed
  • Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat 2012; 135:893-906. PubMed
  • Freedman RA, Anders CK. Treatment of Breast Cancer Brain Metastases. Curr Breast Cancer Rep 2012; 4:1-9. PubMed
  • Freedman RA, Virgo KS, He Y, Pavluck AL, Winer EP, Ward EM, Keating NL. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer 2010; 117:180-9. PubMed
  • Freedman RA, Winer EP. Adjuvant therapy for postmenopausal women with endocrine-sensitive breast cancer. Breast 2010; 19:69-75. PubMed
  • Freedman RA,He Y,Winer EP,Keating NL. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 2008; 27:713-9. PubMed
  • Freedman RA,Winer EP. Reducing disparities in breast cancer care: a daunting but essential responsibility. Journal of the National Cancer Institute 2008; 100:1661-3. PubMed
  • Freedman RA,Bauer KA,Neuberg DS,Zwicker JI. Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. Blood Coagul Fibrinolysis 2008; 19:55-9. PubMed
  • Freedman RA, Wirth LJ, Chirieac LR, Huang EC. Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol 2007; 25:2848-50. PubMed
Hide